Conlon K C, Urba W J, Smith J W, Steis R G, Longo D L, Clark J W
Division of Cancer Treatment, National Cancer Institute-Frederick Cancer Research Facility, Maryland 21701.
Cancer. 1990 May 15;65(10):2237-42. doi: 10.1002/1097-0142(19900515)65:10<2237::aid-cncr2820651013>3.0.co;2-5.
The occurrence of autoimmune disease in patients receiving alpha-interferon (alpha-IFN) therapy has been reported in several studies; these include autoimmune thyroiditis, thrombocytopenia, anemia, exacerbation of psoriasis, and the occurrence of sarcoidosis. The primary mechanism presumably is the emergence of autoantibodies to various structural proteins or receptors. Two studies have recently shown that a significant percentage of patients treated with recombinant alpha-interferon (r alpha-IFN) do form autoantibodies. The authors report six additional cases of development or exacerbation of autoimmune phenomena in patients receiving alpha-IFN therapy. Five of these patients developed symmetric polyarthropathies and the sixth had thyroiditis. The presence of a history of underlying autoimmune disease or baseline serologic abnormalities in five of these patients, including the patient who developed thyroiditis, suggests that alpha-IFN treatment can lead to the exacerbation of an underlying subclinical autoimmune process.
多项研究报道了接受α-干扰素(α-IFN)治疗的患者中自身免疫性疾病的发生情况;这些疾病包括自身免疫性甲状腺炎、血小板减少症、贫血、银屑病加重以及结节病的发生。推测其主要机制是针对各种结构蛋白或受体的自身抗体的出现。最近两项研究表明,接受重组α-干扰素(rα-IFN)治疗的患者中有相当比例确实会形成自身抗体。作者报告了另外6例接受α-IFN治疗的患者出现自身免疫现象或病情加重的病例。其中5例患者出现对称性多关节病,第6例患有甲状腺炎。这些患者中有5例,包括患甲状腺炎的患者,有潜在自身免疫性疾病史或基线血清学异常,这表明α-IFN治疗可导致潜在的亚临床自身免疫过程加重。